Health Care • Biotechnology: Pharmaceutical Preparations
$2.29 ▼ -0.07
(-2.97%)
MKT CAP: $499.0M • VOL: 4.63M
52W L $2 52W H $8
CTMX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $76.2M | $138.1M | $101.2M |
| YoY Revenue Growth % | -44.8% | +36.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.4M | $25.0M | -$6.5M |
| Operating Margin % | -29.3% | 18.1% | -6.4% |
| Net Income (GAAP) | -$17.4M | $31.9M | -$569.0K |
| EBITDA (Normalized) | -$22.2M | $25.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$75.6M | -$86.2M | -$56.0M |
| Capital Expenditures (CapEx) | $220.0K | $310.0K | — |
| Free Cash Flow (FCF) | -$75.8M | -$86.5M | -$56.0M |
| FCF Margin % | -80.0% | -62.7% | -55.4% |
| Return on Invested Capital (ROIC %) | -20.5% | 95.0% | — |
| Cash & Short-Term Equivalents | $12.7M | $38.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $99.0M | -$456.0K | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CTMX.